Serum interleukin-10 levels in patients affected with multiple myeloma

Correlation with the monoclonal component and disease progression

F. Ameglio, S. Alvino, E. Trento, M. Marcucci, F. Pimpinelli, A. W. Tong, G. M. Gandolfo, C. Greco

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Using a commercially available, competitive ELISA kit based on a polyclonal anti-interleukin-10 antibody, serum interleukin-10 (IL-10) levels were quantified in samples of different groups of patients: 20 healthy controls (CTR), 11 monoclonal gammopathies of uncertain significance (MGUS), 17 multiple myelomas (MM), 10 cancer patients (CANCER), 13 cancer patients + MGUS (MGUS-CA) and 7 MGUS patients after surgical removal of concomitant cancer (MGUS-SRCC). Results show significant differences of both the median levels of IL-10 and the monoclonal component (MC) in CTR, MGUS and MM (patients with increasing concentrations in the mentioned order). The IL-10 levels found in the three groups of cancer patients showed serum levels higher than those observed in the controls. Moreover, the surgical cancer removal was related to an IL-10 decrease. A highly significant correlation between serum IL-10 levels and the corresponding MC was also found in the MM-bearing patients and to a lesser extent, in MGUS patients, indicating that serum IL-10 is parallel to the amount of the activated clone causing the monoclonal gammopathy. Since human myeloma lines, cultured in vitro may release significant amounts of IL-10, the data presented support the hypothesis that serum IL-10, measured in myelomatous patients may, at least in part, derive from the activated clone causing the monoclonal gammopathy.

Original languageEnglish
Pages (from-to)1189-1192
Number of pages4
JournalInternational Journal of Oncology
Volume6
Issue number6
Publication statusPublished - 1995

Fingerprint

Paraproteinemias
Multiple Myeloma
Interleukin-10
Disease Progression
Serum
Neoplasms
Clone Cells
Enzyme-Linked Immunosorbent Assay
Antibodies

Keywords

  • IL-10
  • Monoclonal component
  • Monoclonal gammopathy of uncertain significance
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Serum interleukin-10 levels in patients affected with multiple myeloma : Correlation with the monoclonal component and disease progression. / Ameglio, F.; Alvino, S.; Trento, E.; Marcucci, M.; Pimpinelli, F.; Tong, A. W.; Gandolfo, G. M.; Greco, C.

In: International Journal of Oncology, Vol. 6, No. 6, 1995, p. 1189-1192.

Research output: Contribution to journalArticle

@article{518087423a8844f2b5091b49d7aa0ffa,
title = "Serum interleukin-10 levels in patients affected with multiple myeloma: Correlation with the monoclonal component and disease progression",
abstract = "Using a commercially available, competitive ELISA kit based on a polyclonal anti-interleukin-10 antibody, serum interleukin-10 (IL-10) levels were quantified in samples of different groups of patients: 20 healthy controls (CTR), 11 monoclonal gammopathies of uncertain significance (MGUS), 17 multiple myelomas (MM), 10 cancer patients (CANCER), 13 cancer patients + MGUS (MGUS-CA) and 7 MGUS patients after surgical removal of concomitant cancer (MGUS-SRCC). Results show significant differences of both the median levels of IL-10 and the monoclonal component (MC) in CTR, MGUS and MM (patients with increasing concentrations in the mentioned order). The IL-10 levels found in the three groups of cancer patients showed serum levels higher than those observed in the controls. Moreover, the surgical cancer removal was related to an IL-10 decrease. A highly significant correlation between serum IL-10 levels and the corresponding MC was also found in the MM-bearing patients and to a lesser extent, in MGUS patients, indicating that serum IL-10 is parallel to the amount of the activated clone causing the monoclonal gammopathy. Since human myeloma lines, cultured in vitro may release significant amounts of IL-10, the data presented support the hypothesis that serum IL-10, measured in myelomatous patients may, at least in part, derive from the activated clone causing the monoclonal gammopathy.",
keywords = "IL-10, Monoclonal component, Monoclonal gammopathy of uncertain significance, Multiple myeloma",
author = "F. Ameglio and S. Alvino and E. Trento and M. Marcucci and F. Pimpinelli and Tong, {A. W.} and Gandolfo, {G. M.} and C. Greco",
year = "1995",
language = "English",
volume = "6",
pages = "1189--1192",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Serum interleukin-10 levels in patients affected with multiple myeloma

T2 - Correlation with the monoclonal component and disease progression

AU - Ameglio, F.

AU - Alvino, S.

AU - Trento, E.

AU - Marcucci, M.

AU - Pimpinelli, F.

AU - Tong, A. W.

AU - Gandolfo, G. M.

AU - Greco, C.

PY - 1995

Y1 - 1995

N2 - Using a commercially available, competitive ELISA kit based on a polyclonal anti-interleukin-10 antibody, serum interleukin-10 (IL-10) levels were quantified in samples of different groups of patients: 20 healthy controls (CTR), 11 monoclonal gammopathies of uncertain significance (MGUS), 17 multiple myelomas (MM), 10 cancer patients (CANCER), 13 cancer patients + MGUS (MGUS-CA) and 7 MGUS patients after surgical removal of concomitant cancer (MGUS-SRCC). Results show significant differences of both the median levels of IL-10 and the monoclonal component (MC) in CTR, MGUS and MM (patients with increasing concentrations in the mentioned order). The IL-10 levels found in the three groups of cancer patients showed serum levels higher than those observed in the controls. Moreover, the surgical cancer removal was related to an IL-10 decrease. A highly significant correlation between serum IL-10 levels and the corresponding MC was also found in the MM-bearing patients and to a lesser extent, in MGUS patients, indicating that serum IL-10 is parallel to the amount of the activated clone causing the monoclonal gammopathy. Since human myeloma lines, cultured in vitro may release significant amounts of IL-10, the data presented support the hypothesis that serum IL-10, measured in myelomatous patients may, at least in part, derive from the activated clone causing the monoclonal gammopathy.

AB - Using a commercially available, competitive ELISA kit based on a polyclonal anti-interleukin-10 antibody, serum interleukin-10 (IL-10) levels were quantified in samples of different groups of patients: 20 healthy controls (CTR), 11 monoclonal gammopathies of uncertain significance (MGUS), 17 multiple myelomas (MM), 10 cancer patients (CANCER), 13 cancer patients + MGUS (MGUS-CA) and 7 MGUS patients after surgical removal of concomitant cancer (MGUS-SRCC). Results show significant differences of both the median levels of IL-10 and the monoclonal component (MC) in CTR, MGUS and MM (patients with increasing concentrations in the mentioned order). The IL-10 levels found in the three groups of cancer patients showed serum levels higher than those observed in the controls. Moreover, the surgical cancer removal was related to an IL-10 decrease. A highly significant correlation between serum IL-10 levels and the corresponding MC was also found in the MM-bearing patients and to a lesser extent, in MGUS patients, indicating that serum IL-10 is parallel to the amount of the activated clone causing the monoclonal gammopathy. Since human myeloma lines, cultured in vitro may release significant amounts of IL-10, the data presented support the hypothesis that serum IL-10, measured in myelomatous patients may, at least in part, derive from the activated clone causing the monoclonal gammopathy.

KW - IL-10

KW - Monoclonal component

KW - Monoclonal gammopathy of uncertain significance

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=0029054223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029054223&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 1189

EP - 1192

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -